CytomX Therapeutics (CTMX) Interest Coverage Ratio (2014 - 2017)
CytomX Therapeutics (CTMX) reported Interest Coverage Ratio of 41.82 for Q1 2017, up 8.78% on a YoY basis from 38.44 in Q1 2016, and down 14.31% quarter-over-quarter from 36.58 in Q4 2016.
CytomX Therapeutics (CTMX) Interest Coverage Ratio (2014 - 2017) Analysis & Trends
CytomX Therapeutics has reported Interest Coverage Ratio for 4 years, with the latest figure at 41.82 in Q1 2017.
- For the quarter ending Q1 2017, Interest Coverage Ratio rose 8.78% year-over-year to 41.82; the trailing twelve-month figure through Dec 2017 stood at 224.56 (down 536.52% YoY), and the FY2016 full-year result was 35.28, down 84.03% from the prior year.
- Interest Coverage Ratio for Q1 2017 stood at 41.82, down from 36.58 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 13.58 in Q2 2015, with the low at 45.84 in Q1 2016.
- Historically, Interest Coverage Ratio has averaged 30.84 across 4 years, with a median of 30.66 in 2016.
- Annual changes were most pronounced in 2015 — Interest Coverage Ratio soared 46.99% — and 2016, when it tumbled 125.74%.
- CytomX Therapeutics' Interest Coverage Ratio stood at 42.74 in 2014, then advanced by 28.3% to 30.65 in 2015, then decreased by 19.35% to 36.58 in 2016, then slipped by 14.31% to 41.82 in 2017.
- The last three Interest Coverage Ratio figures came in at 41.82 (Q1 2017), 36.58 (Q4 2016), and 30.95 (Q3 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -41.82 |
| Dec 31, 2016 | -36.58 |
| Sep 30, 2016 | -30.95 |
| Jun 30, 2016 | -30.66 |
| Mar 31, 2016 | -45.84 |
| Dec 31, 2015 | -30.65 |
| Sep 30, 2015 | -15.69 |
| Jun 30, 2015 | -13.58 |
| Mar 31, 2015 | -21.17 |
| Dec 31, 2014 | -42.74 |
| Sep 30, 2014 | -29.61 |